+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Obsessive-Compulsive Disorder Drugs Market by Drug Class (MAOIs, SNRIs, SSRIs), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Drug Type, Route Of Administration, End User, Patient Age Group - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 194 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5716358
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Obsessive-Compulsive Disorder Drugs Market grew from USD 969.71 million in 2024 to USD 1.05 billion in 2025. It is expected to continue growing at a CAGR of 8.67%, reaching USD 1.59 billion by 2030.

Delivering a Comprehensive Overview of the Obsessive-Compulsive Disorder Therapeutics Landscape with Perspective on Efficacy Trends and Treatment Challenges

Obsessive-compulsive disorder represents a complex psychiatric condition characterized by intrusive thoughts and repeated behaviors that significantly impair daily functioning. Effective pharmacological management lies at the heart of improving patient outcomes, driving ongoing research into novel therapeutic approaches. In recent years, the evolution of drug classes targeting monoamine oxidase, serotonin reuptake, and norepinephrine pathways has reshaped clinical protocols. The nuanced interplay between efficacy, safety, and tolerability remains a critical consideration for clinicians seeking to optimize treatment regimens across varied patient populations.

Moreover, rising awareness of patient heterogeneity has underscored the importance of personalized medicine in obsessive-compulsive disorder care. Advances in understanding the neurobiological underpinnings of compulsive behaviors have validated existing selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, and monoamine oxidase inhibitors while informing the development of next-generation compounds. Simultaneously, the demand for accessible distribution channels, including hospital pharmacies, online platforms, and retail outlets, has grown in tandem with broader trends toward digital health delivery.

In parallel, the expanding portfolio of generics has injected competitive pricing into the market while challenging brand-name manufacturers to demonstrate superior clinical profiles. Providers must weigh the benefits of established oral formulations against potential opportunities presented by parenteral delivery systems for patients with limited gastrointestinal tolerance or severe symptomatology.

Demographic considerations also drive treatment decisions, as adult and pediatric cohorts often respond differently to specific compounds. Regulatory guidelines and clinical trial designs tailored to these age groups are critical for ensuring safety and efficacy. In addition, the role of primary care clinics, specialized hospital units, and home-based care models continues to evolve as stakeholders seek to lower barriers to treatment initiation and long-term adherence.

This introductory section sets the stage for an in-depth examination of how emerging data, tariff shifts, and segmentation-driven insights are reshaping the future of obsessive-compulsive disorder pharmacotherapy.

Revolutionary Shifts in Treatment Modalities for Obsessive-Compulsive Disorder Driven by Mechanism of Action Breakthroughs and Patient-Centered Innovations

Recent years have witnessed an accelerating pace of innovation in obsessive-compulsive disorder therapeutics, propelled by a deeper understanding of neurotransmitter interactions and genetic markers. Next-generation selective serotonin reuptake inhibitors are being optimized through molecular modifications that enhance receptor selectivity and minimize side effects. At the same time, novel serotonin-norepinephrine reuptake inhibitors are emerging from late-stage clinical trials with improved pharmacokinetic profiles that promise faster onset of action. Concurrent research into reversible monoamine oxidase inhibitors seeks to preserve dietary flexibility while maintaining robust enzyme inhibition.

Furthermore, pharmaceutical developers have renewed interest in modular tricyclic frameworks, leveraging modern medicinal chemistry techniques to revisit amitriptyline analogs with improved safety margins. This renaissance in compound design reflects a broader industry shift toward mechanism-specific therapies, complemented by advanced screening platforms that integrate in vitro assays with computational modeling. As a result, stakeholders can more accurately predict clinical performance and streamline candidate selection.

The patient experience has also become a central driver of therapeutic innovation. Digital adherence tools and telemedicine consultations are increasingly integrated with pharmacotherapy regimens to support monitoring and real-time dose adjustments. Such hybrid care models not only enhance treatment compliance but also generate rich data for refining personalized therapeutic pathways.

Moreover, the convergence of neuroscience and immunology has opened exploratory avenues for adjunctive therapies that target inflammatory pathways implicated in obsessive-compulsive disorder. Early-stage studies investigating the efficacy of anti-inflammatory compounds and neuroimmune modulators suggest potential synergistic effects when combined with traditional antidepressant agents. These approaches reflect a transformative shift from symptomatic management to a more holistic intervention strategy designed to address the multifaceted etiology of compulsive behaviors.

Collectively, these advancements illustrate a dynamic landscape in which scientific breakthroughs, patient-centric innovation, and multidisciplinary collaboration converge to redefine standards of care in obsessive-compulsive disorder treatment.

Assessing the Impact of United States Trade Tariffs on Obsessive-Compulsive Disorder Drug Supply Chains Pricing Strategies and Market Accessibility in 2025

Implementation of new United States tariffs in 2025 has triggered a reassessment of supply chain strategies for obsessive-compulsive disorder drugs. Many active pharmaceutical ingredients sourced from overseas manufacturing hubs now face increased import duties, prompting companies to explore alternative procurement channels and domestic production capacity expansions. In response, several manufacturers have initiated nearshoring efforts, negotiating partnerships with US-based chemical suppliers and contract manufacturers to safeguard pipeline continuity and mitigate cost pressure.

These tariff adjustments have influenced cost structures across distribution channels. Hospital pharmacies, which traditionally rely on bulk purchasing agreements, are experiencing incremental pricing adjustments that may affect formulary decisions. Online pharmacies, in contrast, leverage broader global networks to offset duties through diversified sourcing, offering a degree of pricing flexibility that benefits end users. Retail pharmacy networks are similarly adapting by renegotiating supplier contracts to pass minimal cost increases to consumers while preserving margins.

At the same time, the new trade landscape has intensified the strategic importance of generic drug producers. Lower-margin formulations are particularly sensitive to raw material price fluctuations, with some manufacturers absorbing duties to maintain competitive positioning. Conversely, brand-name innovators are employing cost-recovery strategies that include incremental price adjustments tied to tariff metrics-a practice that has prompted dialogue with regulatory bodies regarding fair pricing practices and patient access considerations.

Overall, the cumulative impact of these measures underscores the need for agile supply chain governance. Stakeholders must balance tariff-induced cost fluctuations with commitments to reliability, safety, and therapeutic consistency. Looking ahead, scenario planning and dynamic pricing models will be essential tools for maintaining market stability and ensuring uninterrupted patient access to critical obsessive-compulsive disorder treatments.

In-Depth Segmentation Analysis Uncovering How Drug Class Distribution Channels and Demographic Criteria Shape Obsessive-Compulsive Disorder Therapeutic Utilization Patterns

Understanding the multifaceted nature of obsessive-compulsive disorder therapeutics requires a deep dive into segmentation variables that drive market dynamics. Drug class distinctions illuminate how monoamine oxidase inhibitors, serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, and tricyclic antidepressants perform across clinical applications and patient subsets. Within the MAOI category, compounds such as phenelzine and tranylcypromine continue to serve refractory cases, while within the SNRI category, desvenlafaxine, duloxetine, and venlafaxine exhibit varying neurochemical profiles that influence tolerance and efficacy. In the SSRI cohort, agents including citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline remain foundational due to their established safety records and robust evidence base. Tricyclic agents like amitriptyline, clomipramine, and imipramine, although older, retain clinical relevance in treatment-resistant populations.

The distribution channel dimension further refines strategic approaches, contrasting hospital pharmacy procurement protocols with the agility of online pharmacy platforms and the widespread availability of retail pharmacies. This channel diversity affects everything from inventory planning to patient engagement strategies. Drug type segmentation between proprietary brand formulations and lower-cost generics underscores the tension between innovation and affordability in therapy adoption. The route of administration variable differentiates oral therapies, which dominate prescribing patterns, from parenteral options that are reserved for acute or specialized clinical scenarios.

Patient demographics also play a central role. End users span from primary care clinics to specialized hospital units and home treatment settings, each with unique formulary and compliance considerations. Age group segmentation highlights the diverging safety and efficacy needs of adult versus pediatric populations, underscoring the importance of age-appropriate trial design and dosage optimization.

Together, these segmentation insights offer a comprehensive framework for stakeholders to tailor product development, marketing, and distribution strategies that address the diverse requirements of obsessive-compulsive disorder treatment programs.

Critical Regional Perspectives Revealing Diverse Regulatory Environments and Adoption Trends for Obsessive-Compulsive Disorder Therapies Across Global Geographies

Regional dynamics shape the adoption and accessibility of obsessive-compulsive disorder treatments, reflecting variations in regulatory frameworks, healthcare infrastructure, and cultural factors. In the Americas, established reimbursement pathways and integrated healthcare networks support broad formulary inclusion of leading selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors. The prevalence of specialty clinics and telehealth platforms in North America fosters rapid uptake of digital adherence tools and novel therapeutic combinations, while emerging markets in Latin America focus on expanding access to generics and optimizing cost-efficiency through public-private partnerships.

Across Europe, the Middle East, and Africa, heterogeneous regulatory environments and reimbursement policies require tailored market entry strategies. Western European nations often demand extensive real-world evidence to secure favorable pricing for brand-name compounds, driving collaboration between manufacturers and regional health technology assessment bodies. In contrast, certain Middle Eastern markets emphasize expedited approvals and strategic alliances with local distributors to navigate diverse regulatory landscapes. Across sub-Saharan Africa, limited infrastructure continues to constrain widespread availability of advanced formulations, prompting reliance on oral generics and outreach programs to address unmet clinical needs.

In the Asia-Pacific region, rapid regulatory reform and growing pharmaceutical manufacturing capabilities are transforming access to innovative therapies. Developed markets such as Japan and Australia balance stringent clinical standards with incentives for breakthrough designations, supporting the launch of novel mechanism-based compounds. Meanwhile, markets in Southeast Asia and India leverage robust generic industries to maintain affordability, even as they invest in expanding clinical trial capacity and regulatory harmonization initiatives.

These regional insights underscore the importance of flexible strategies that align product profiles, pricing models, and distribution architectures with localized market conditions, ensuring that patients worldwide can benefit from advancements in obsessive-compulsive disorder pharmacotherapy.

Strategic Company Profiles Highlighting Market Leadership and R&D Initiatives of Key Pharmaceutical Innovators in the Obsessive-Compulsive Disorder Treatment Arena

Leading pharmaceutical companies are driving competitive dynamics in the obsessive-compulsive disorder drug market through differentiated research and strategic collaborations. Major multinational developers continue to invest in expanding their selective serotonin reuptake inhibitor portfolios, leveraging proprietary delivery technologies and extended-release formulations to maintain clinical leadership. These innovators engage in strategic partnerships with biotechnology firms and academic institutions to accelerate early-stage discovery of novel compounds targeting neurotransmitter systems beyond serotonin reuptake.

At the same time, specialized mid-size companies focus on niche segments, such as reversible monoamine oxidase inhibitors and adjunctive neuroimmune modulators. Their agility in clinical development and targeted pipeline prioritization enables them to address specific treatment gaps, particularly in refractory and pediatric populations. By forging alliances with contract research organizations and global regulatory consultants, these players can fast-track investigational therapeutics through pivotal trials and regulatory submissions.

Generic manufacturers also play a pivotal role by ensuring continued access to established agents. Their robust production capabilities and supply chain resilience offer cost-effective alternatives, which help alleviate pricing pressures and expand treatment affordability. In turn, this competitive intensity stimulates brand-name developers to emphasize clinical differentiation, patient support services, and evidence generation to justify premium positioning.

Emerging biotech firms are reshaping the landscape through innovative drug delivery platforms and data-driven approaches. By integrating digital biomarkers and real-world evidence into their development strategies, these companies refine patient stratification and optimize trial design. Such methods enhance the probability of regulatory approval and support compelling value propositions to payers and prescribers.

Collectively, these company strategies reflect a market in which both scale and specialization drive therapeutic progress, underscoring the need for continuous innovation and strategic collaboration across the value chain.

Action-Oriented Strategic Imperatives Enabling Industry Stakeholders to Leverage Emerging Therapeutic Advances and Navigate Regulatory Complexities in OCD Treatment Development

Industry leaders seeking to capitalize on the rapid evolution of obsessive-compulsive disorder therapeutics should prioritize investment in mechanism-specific research that addresses unmet clinical needs. Allocating resources toward novel serotonin-norepinephrine reuptake inhibitors and reversible monoamine oxidase inhibitors with enhanced safety profiles can yield differentiated assets in a competitive marketplace. Likewise, supporting modular tricyclic antidepressant programs with modernized chemical scaffolds can provide valuable options for treatment-resistant patients.

In parallel, optimizing distribution strategies will be critical to maximizing market penetration. Strengthening partnerships with hospital pharmacy networks will ensure reliable supply for inpatient and specialized settings, while enhancing online pharmacy integrations can expand patient access through digital channels. Retail pharmacy collaborations should focus on patient education initiatives to improve adherence and support the transition from acute care to maintenance therapy.

A focus on data-driven patient engagement is essential. Implementing digital adherence monitoring and telehealth support programs will generate actionable insights into real-world usage patterns, enabling adaptive dose management and personalized treatment pathways. Furthermore, collaboration with regulatory authorities to establish clear guidelines for pediatric and geriatric trial designs can de-risk development timelines and accelerate approvals for priority patient segments.

Finally, proactive scenario planning for trade and tariff shifts will safeguard supply chain resilience. Developing dynamic pricing models and regional manufacturing alliances will help manage cost volatility and maintain therapeutic consistency. By embracing these strategic imperatives, stakeholders can navigate regulatory complexities, drive clinical differentiation, and deliver sustainable value in the obsessive-compulsive disorder market.

Robust Mixed Methods Research Framework Detailing Data Collection Analytical Techniques and Validation Processes for the Obsessive-Compulsive Disorder Drug Market Study

The research methodology underpinning this comprehensive study employs a robust mixed methods framework designed to ensure data integrity and analytical depth. Primary research involved in-depth interviews with key opinion leaders, clinical trial investigators, and supply chain executives to capture nuanced perspectives on therapeutic innovation, market access, and distribution trends. This qualitative input was supplemented by a systematic review of peer-reviewed journals, regulatory filings, and conference proceedings to validate emerging scientific data and competitive intelligence.

Secondary research entailed the aggregation of global regulatory databases, patent registries, and industry publications to map the historical evolution of drug approvals and identify shifts in policy frameworks. Key performance indicators such as clinical trial success rates, time to market, and safety signal profiles were extracted and normalized across sources to facilitate comparative analysis. Data triangulation techniques were applied to reconcile discrepancies, ensure consistency, and enhance the robustness of insights.

Quantitative modeling incorporated scenario planning for tariff impacts, pricing elasticity analyses, and channel-specific uptake projections. Statistical methodologies, including regression analysis and cluster segmentation, were utilized to interpret driver correlations and forecast adoption patterns across patient demographics and regions. Throughout the process, a cross-functional review board oversaw methodological rigor, ensuring transparency in data collection, reproducibility of results, and adherence to ethical standards.

The result is a meticulously validated framework that offers stakeholders a clear roadmap for informed decision-making, leveraging both empirical evidence and expert judgment to illuminate the future trajectory of obsessive-compulsive disorder pharmacotherapy.

Conclusive Reflections Emphasizing the Synergistic Role of Therapeutic Innovation and Collaborative Stakeholder Engagement in Transforming Obsessive-Compulsive Disorder Care

In conclusion, the landscape of obsessive-compulsive disorder treatment is poised for significant transformation driven by scientific innovation, patient-centric care models, and adaptive market strategies. Emerging therapies that target specific neurotransmitter pathways, coupled with adjunctive approaches that address neuroimmune mechanisms, offer promising avenues to improve clinical outcomes and quality of life for patients across diverse demographics.

Strategic segmentation insights underscore the importance of tailoring drug development and commercialization efforts to the unique requirements of each therapy class, distribution channel, and patient subgroup. Regional considerations further highlight the need for flexible regulatory strategies and dynamic partnerships to align with localized market conditions and healthcare infrastructure.

Leading companies are responding to these trends by forging collaborative networks, advancing novel delivery platforms, and harnessing real-world data to refine patient pathways. By integrating actionable recommendations into strategic planning, stakeholders can mitigate regulatory and tariff-related challenges, optimize access through digital and retail channels, and drive sustainable growth in an increasingly competitive environment.

Ultimately, coordinated efforts across research, commercial, and stakeholder engagement functions will be essential to unlocking the full therapeutic potential of obsessive-compulsive disorder interventions and paving the way for the next generation of innovative treatments.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Class
    • MAOIs
      • Phenelzine
      • Tranylcypromine
    • SNRIs
      • Desvenlafaxine
      • Duloxetine
      • Venlafaxine
    • SSRIs
      • Citalopram
      • Fluoxetine
      • Fluvoxamine
      • Paroxetine
      • Sertraline
    • TCAs
      • Amitriptyline
      • Clomipramine
      • Imipramine
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Drug Type
    • Brand
    • Generic
  • Route Of Administration
    • Oral
    • Parenteral
  • End User
    • Clinics
    • Hospitals
    • Households
  • Patient Age Group
    • Adult
    • Pediatric
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Pfizer Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • H. Lundbeck A/S
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Johnson & Johnson

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rise of psychedelic-assisted therapies like psilocybin in clinical trials for treatment-resistant OCD
5.2. Increased utilization of digital therapeutics and telepsychiatry platforms for remote OCD symptom management
5.3. Advancements in precision medicine strategies using genetic biomarkers to predict OCD drug response
5.4. Growing focus on glutamate-modulating agents as novel mechanisms of action in OCD treatment pipelines
5.5. Expansion of real-world evidence and patient-reported outcome data influencing OCD drug reimbursement decisions
5.6. Regulatory momentum for fast-track designations and orphan drug status in severe OCD therapeutic candidates
5.7. Competitive pricing pressures driving development of generic and biosimilar alternatives to established SSRIs
5.8. Rising investment in combination therapy trials pairing pharmacologics with cognitive behavioral interventions for OCD
5.9. Emerging market expansion in Asia-Pacific and Latin America as new growth avenues for OCD therapeutics
5.10. Pediatric and adolescent-focused OCD drug research accelerating child-specific formulation development and approval
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Obsessive-Compulsive Disorder Drugs Market, by Drug Class
8.1. Introduction
8.2. MAOIs
8.2.1. Phenelzine
8.2.2. Tranylcypromine
8.3. SNRIs
8.3.1. Desvenlafaxine
8.3.2. Duloxetine
8.3.3. Venlafaxine
8.4. SSRIs
8.4.1. Citalopram
8.4.2. Fluoxetine
8.4.3. Fluvoxamine
8.4.4. Paroxetine
8.4.5. Sertraline
8.5. TCAs
8.5.1. Amitriptyline
8.5.2. Clomipramine
8.5.3. Imipramine
9. Obsessive-Compulsive Disorder Drugs Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
10. Obsessive-Compulsive Disorder Drugs Market, by Drug Type
10.1. Introduction
10.2. Brand
10.3. Generic
11. Obsessive-Compulsive Disorder Drugs Market, by Route Of Administration
11.1. Introduction
11.2. Oral
11.3. Parenteral
12. Obsessive-Compulsive Disorder Drugs Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Hospitals
12.4. Households
13. Obsessive-Compulsive Disorder Drugs Market, by Patient Age Group
13.1. Introduction
13.2. Adult
13.3. Pediatric
14. Americas Obsessive-Compulsive Disorder Drugs Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Obsessive-Compulsive Disorder Drugs Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Obsessive-Compulsive Disorder Drugs Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Pfizer Inc.
17.3.2. Eli Lilly and Company
17.3.3. GlaxoSmithKline plc
17.3.4. H. Lundbeck A/S
17.3.5. Teva Pharmaceutical Industries Ltd.
17.3.6. Novartis AG
17.3.7. Sun Pharmaceutical Industries Ltd.
17.3.8. Viatris Inc.
17.3.9. Otsuka Pharmaceutical Co., Ltd.
17.3.10. Johnson & Johnson
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 8. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 16. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET: RESEARCHAI
FIGURE 28. OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 29. OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET: RESEARCHCONTACTS
FIGURE 30. OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PHENELZINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PHENELZINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TRANYLCYPROMINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TRANYLCYPROMINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DESVENLAFAXINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DESVENLAFAXINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DULOXETINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DULOXETINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY VENLAFAXINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY VENLAFAXINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CITALOPRAM, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CITALOPRAM, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUOXETINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUOXETINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUVOXAMINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUVOXAMINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PAROXETINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PAROXETINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SERTRALINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SERTRALINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY AMITRIPTYLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY AMITRIPTYLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLOMIPRAMINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLOMIPRAMINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY IMIPRAMINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY IMIPRAMINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY BRAND, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY BRAND, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOUSEHOLDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOUSEHOLDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 131. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 132. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 133. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2024 (USD MILLION)
TABLE 134. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2025-2030 (USD MILLION)
TABLE 135. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
TABLE 136. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2025-2030 (USD MILLION)
TABLE 137. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2024 (USD MILLION)
TABLE 138. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2025-2030 (USD MILLION)
TABLE 139. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
TABLE 140. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2025-2030 (USD MILLION)
TABLE 141. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 142. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 143. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 144. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 145. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 146. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 147. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 148. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 149. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 150. CANADA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 151. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 152. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 153. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2024 (USD MILLION)
TABLE 154. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2025-2030 (USD MILLION)
TABLE 155. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
TABLE 156. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2025-2030 (USD MILLION)
TABLE 157. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2024 (USD MILLION)
TABLE 158. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2025-2030 (USD MILLION)
TABLE 159. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
TABLE 160. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2025-2030 (USD MILLION)
TABLE 161. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 162. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 163. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 164. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 165. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 166. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 167. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 168. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 169. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 170. MEXICO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2025-2030 (USD MILLION)
TABLE 181. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 182. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 183. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 184. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 185. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 186. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 187. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 188. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 189. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 190. BRAZIL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2025-2030 (USD MILLION)
TABLE 195. ARGENTINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
TABLE 196. ARGENTINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2025-2030 (USD MILLION)
TABLE 199. ARGENTINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
TABLE 200. ARGENTINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2025-2030 (USD MILLION)
TABLE 201. ARGENTINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 202. ARGENTINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 203. ARGENTINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 204. ARGENTINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 205. ARGENTINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 206. ARGENTINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 207. ARGENTINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 208. ARGENTINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 209. ARGENTINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 210. ARGENTINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2025-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2025-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2024 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2025-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2025-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 234. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2024 (USD MILLION)
TABLE 236. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2025-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
TABLE 238. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2025-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2024 (USD MILLION)
TABLE 240. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2025-2030 (USD MILLION)
TABLE 241. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
TABLE 242. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2025-2030 (USD MILLION)
TABLE 243. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 244. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 245. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 246. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 247. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 248. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 249. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 250. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 251. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 252. UNITED KINGDOM OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 253. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 254. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 255. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2024 (USD MILLION)
TABLE 256. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2025-2030 (USD MILLION)
TABLE 257. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
TABLE 258. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2025-2030 (USD MILLION)
TABLE 259. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2024 (USD MILLION)
TABLE 260. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2025-2030 (USD MILLION)
TABLE 261. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
TABLE 262. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2025-2030 (USD MILLION)
TABLE 263. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 264. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 265. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 266. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 267. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 268. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 269. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 270. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 271. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 272. GERMANY OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 273. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 274. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 275. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2024 (USD MILLION)
TABLE 276. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2025-2030 (USD MILLION)
TABLE 277. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
TABLE 278. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2025-2030 (USD MILLION)
TABLE 279. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2024 (USD MILLION)
TABLE 280. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2025-2030 (USD MILLION)
TABLE 281. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
TABLE 282. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2025-2030 (USD MILLION)
TABLE 283. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 284. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 285. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 286. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 287. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 288. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 289. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 290. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 291. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 292. FRANCE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 293. RUSSIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 294. RUSSIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 295. RUSSIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2024 (USD MILLION)
TABLE 296. RUSSIA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2025-2

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Obsessive-Compulsive Disorder Drugs market report include:
  • Pfizer Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • H. Lundbeck A/S
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Johnson & Johnson

Table Information